GlassScriptPhysician profile
Stephanie Benson
NPI 1689303679
$2,482.22
in general payments reported to CMS, 2019-2025
29 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $469 · 2024: $1,020 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.90 | 2022-2025 | |
| Novo Nordisk INC | $547.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $178.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Kyowa Kirin, INC. | $134.33 | 2024-2025 | Crysvita |
| Medtronic, INC. | $110.91 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Otsuka America Pharmaceutical, INC. | $109.71 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $98.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.51 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $80.23 | 2023-2025 | Farxiga, Airsupra |
| Pfizer INC. | $71.53 | 2024-2025 | |
| Glaxosmithkline, LLC. | $48.03 | 2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $47.57 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.65 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $44.63 | 2024-2025 | Trintellix |
| Dexcom, INC. | $43.66 | 2024-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.45 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $35.77 | 2023-2024 | Spravato, Xarelto |
| Ars Pharmaceuticals Operations, INC. | $23.95 | 2025 | Neffy |
| Genzyme Corporation | $20.24 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.27 | 2022 | |
| Viiv Healthcare Company | $18.55 | 2025 | Apretude |
| Currax Pharmaceuticals LLC | $17.86 | 2025 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2022 | |
| Organon LLC | $16.69 | 2022 | |
| Amgen INC. | $15.68 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $15.63 | 2025 | Auvelity |
| Eisai INC. | $15.01 | 2025 | |
| Globus Medical, INC. | $14.50 | 2025 | Senza |
| Paratek Pharmaceuticals, INC. | $13.43 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.